RxDoctor Payments Data

Jeffrey Felt, MD

Rheumatology · Duluth, MNNPI 1508315789

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,440 of the $7,093 with a category attached, or 62.6%. Gilead accounts for 92.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $6,566 and has fallen 99.2% since, to $55 in 2025.

$7,093in general payments, 2019–2025

Across 34 payments — averaging $208.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$7K
  • Johnson & Johnson$148
  • UCB, Inc.$143
  • AbbVie$88
  • Amgen$52
  • Genentech USA, Inc.$33
  • plus $91 from 4 others

What the payments were for

  • Consulting fees$4,44063%
  • Travel & lodging$1,83226%
  • Food & beverage$82112%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead13$6,538
Johnson & Johnson4$148
UCB, Inc.2$143
AbbVie6$88
Amgen(2 entities)2$52
Genentech USA, Inc.2$33
Boehringer Ingelheim1$28
Pfizer2$27
Sanofi1$22
Lilly USA, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,093 in reported general payments places this provider in the 85th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$26,305
Medicare patients
150
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab80$579,851
Enbrel SureclickEtanercept65$480,541
Orencia ClickjectAbatacept40$222,007
Cosentyx Sensoready (2 Pens)Secukinumab29$211,357
RinvoqUpadacitinib26$175,390
Xeljanz XrTofacitinib Citrate19$104,543
Humira PenAdalimumab14$89,251
Humira(Cf)Adalimumab12$80,471
OtezlaApremilast13$63,215
OlumiantBaricitinib13$36,207
Hydroxychloroquine Sulfate496$26,649
MethotrexateMethotrexate Sodium613$17,530
Leflunomide226$11,138
Prednisone855$9,677
Mycophenolate Mofetil31$4,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$88$255,86138 claims
AmgenOtezla$52$63,21513 claims
Lilly USA, LLCOlumiant$14$36,20713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →